Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-alpha plasma levels in individuals with type 2 diabetes mellitus.
OBJECTIVE
The aim of the study was to evaluate the effect of gliclazide modified release (MR) treatment on adiponectin, interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) plasma concentrations in type 2 diabetic patients.


METHODS
24 randomly selected type 2 diabetic patients, aged 61.2 +/- 15.4 years, with poorly controlled glucose level (mean glycated hemoglobin [HbA1c] 7.6 +/- 1.1%) despite treatment with diet and/or oral hypoglycemic agents, were included in the study. All of the patients, after a 2-week run-in period, were given gliclazide MR for 12 weeks. At baseline, and after gliclazide MR treatment, HbA(1c) and plasma concentrations of IL-6, TNF-alpha, and adiponectin were measured.


RESULTS
Gliclazide MR treatment produced significant reductions in fasting plasma glucose (from 7.6 +/- 1.4 to 6.6 +/- 1.2 mmol/L, p < 0.01), HbA(1c) (from 7.6 +/- 1.1 to 6.9 +/- 0.8%, p < 0.01), and plasma IL-6 concentrations (from 2.5 +/- 1.8 to 1.8 +/- 1.2 pg/mL, p < 0.05). A significant increase in plasma adiponectin level was noted (from 6.4 +/- 3.3 to 7.6 +/- 4.4 mug/mL, p < 0.05). Plasma TNF-alpha concentrations and homeostasis model assessment of insulin resistance (HOMA-IR) decreased after treatment, but these changes did not reach statistical significance.


CONCLUSIONS
Gliclazide MR improves glycemic control and, in addition, has a positive influence on the plasma level of some inflammatory markers and adiponectin. Increased plasma adiponectin and decreased plasma IL-6, and TNF-alpha levels may explain, at least in part, the anti-atherogenic action of this drug reported elsewhere.
Drzewoski
Jozef
J
Department of Internal Medicine, Diabetology and Clinical Pharmacology, Medical University of Łódź, Poland. jdrzew@poczta.onet.pl
Zurawska-Klis
Monika
M
D052242:Adiponectin / Q000097:blood*; D000368:Aged; D001786:Blood Glucose; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005907:Gliclazide / Q000627:therapeutic use*; D006442:Glycated Hemoglobin; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D052242:Adiponectin; D001786:Blood Glucose; D005907:Gliclazide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha